Trial
NCT01232556
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Pfizer
Collaborators
UCB Pharma
Condition
Lymphoma, Non-Hodgkin
Intervention
Inotuzumab ozogamicin
Why stopped
The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected safety issues were identified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-08